Top Markets
Coin of the day
AP Biosciences Inc AP Biosciences Inc

AP Biosciences Inc

6945
Peringkat dalam Saham #16392
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company... AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.
Harga Saham
$3.06
Kapitalisasi Pasar
$296.40M
Perubahan (1 hari)
-2.24%
Perubahan (1 tahun)
-22.64%
Negara
TW
Perdagangan AP Biosciences Inc (6945)

Kategori

Jumlah saham beredar untuk AP Biosciences Inc (6945)
Jumlah saham beredar per September 2026: 0
Menurut laporan keuangan terbaru dan harga saham AP Biosciences Inc, jumlah saham beredar saat ini adalah 0. Pada akhir September 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk AP Biosciences Inc (6945) dari 2026 hingga 2026
Saham beredar pada akhir setiap tahun
Tahun Saham Beredar Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Saham beredar untuk perusahaan serupa atau pesaing
Perusahaan Saham Beredar Perbedaan Negara
253.90M -
US
62.19M -
NL
396.00M -
US
478.91M -
AU
- -
CH